Engineered mRNA Nanoparticle Platforms for Respiratory Mucosal Delivery

Area of Science:

• Immunology
• Nanotechnology
• Vaccinology

Background:

• Respiratory mucosal vaccination offers superior protection against viral infections by inducing immunity at the pathogen's entry site.
• Messenger RNA (mRNA) vaccines are promising due to rapid development and potent immunogenicity.
• Challenges in respiratory mRNA delivery include biological barriers and stringent safety requirements.

Purpose of the Study:

• To evaluate nanoparticle engineering strategies for overcoming respiratory mucosal barriers for mRNA vaccines.
• To improve the safety, stability, delivery efficiency, and immunogenicity of mRNA vaccines and therapeutics for mucosal immunization.
• To review engineered mRNA nanoparticle platforms and optimization strategies for respiratory mucosal immunity.

Main Methods:

• Review of recent advances in nanoparticle engineering for mRNA delivery.
• Summarization of modified lipid nanoparticles (LNPs), polymer-based nanoparticles, and hybrid nanoparticle systems.
• Discussion of optimization strategies including adjuvants, polyethylene glycol (PEG) alternatives, and advanced delivery approaches.

Main Results:

• Nanoparticle engineering can overcome biological barriers in the respiratory tract for enhanced mRNA delivery.
• Various nanoparticle platforms (LNPs, polymer-based, hybrid) show potential for mucosal mRNA immunization.
• Optimization strategies are crucial for improving stability, delivery, and immunogenicity.

Conclusions:

• Nanoparticle engineering is key to developing effective mRNA vaccines for respiratory mucosal delivery.
• Further research is needed to design next-generation platforms for durable and broad mucosal immunity.
• Addressing challenges in safety, stability, and delivery efficiency is critical for clinical translation.